Meningitis (Infectious Disease) - Drugs in Development, 2021

December 2021 | 89 pages | ID: M971BA1D09B5EN
Global Markets Direct

Abstracts

Meningitis (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis – Drugs In Development, 2021, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 5, 4 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Meningitis - Overview
Meningitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Meningitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meningitis - Companies Involved in Therapeutics Development
Meningitis - Drug Profiles
Meningitis - Dormant Projects
Meningitis - Discontinued Products
Meningitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Meningitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Meningitis - Pipeline by CanSino Biologics Inc, 2021
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
Meningitis - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2021
Meningitis - Pipeline by Jiangsu Kunli Biopharmaceutical Co Ltd, 2021
Meningitis - Pipeline by LG Chem Ltd, 2021
Meningitis - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
Meningitis - Pipeline by Linnaeus Bioscience Inc, 2021
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, 2021
Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
Meningitis - Pipeline by Pfizer Inc, 2021
Meningitis - Pipeline by Pneumagen Ltd, 2021
Meningitis - Pipeline by Serum Institute of India Pvt Ltd, 2021
Meningitis - Pipeline by TGV Therapeutics, 2021
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, 2021
Meningitis - Dormant Projects, 2021
Meningitis - Dormant Projects, 2021 (Contd..1)
Meningitis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Meningitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021